<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046136</url>
  </required_header>
  <id_info>
    <org_study_id>2009-MUC-03</org_study_id>
    <nct_id>NCT01046136</nct_id>
  </id_info>
  <brief_title>Mucinex Exploratory Cold Study</brief_title>
  <official_title>Double Blind, Randomized, Placebo Controlled Study of MucinexÂ® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex
      in patients with colds. Patients will receive 7 days of treatment with either Mucinex or
      placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's End of Study Assessment of Treatment</measure>
    <time_frame>7 days</time_frame>
    <description>Yes the investigator would use this treatment for cold symptoms in the future.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in a 6 Point Severity Scale (0 = None, 1 = Very Mild, 2 = Mild or Slight, 3 = Moderate, 4 = Severe or 5 = As Bad as it Can be) for Cough.</measure>
    <time_frame>Baseline and Day 4</time_frame>
    <description>Mean change from baseline in a 6 point severity scale between treatment groups(0 = None, 1 = Very mild, 2 = Mild or slight, 3 = Moderate, 4 = Severe or 5 = As bad as it can be) for cough.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <description>Total number of patients with adverse events that were possibly or probably related.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Mucinex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>guaifenesin (Mucinex)</intervention_name>
    <description>bid 7 days</description>
    <arm_group_label>Mucinex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>bid 7 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  common cold symptoms

          -  meet symptom severity

          -  females of child-bearing potential must have negative pregnancy test and use effective
             birth control

        Exclusion Criteria:

          -  chronic respiratory conditions

          -  significant heart, kidney, liver, or lung disease, uncontrolled hypertension or
             diabetes, cystic fibrosis, thyroid disorder

          -  pregnant or lactating

          -  known malignancy

          -  participation in any other clinical trial within 30 days of baseline

          -  related to another enrolled patient or persons involved directly or indirectly with
             the conduct of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pioneer Clinical Research</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <results_first_submitted>March 3, 2011</results_first_submitted>
  <results_first_submitted_qc>August 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2012</results_first_posted>
  <last_update_submitted>August 24, 2012</last_update_submitted>
  <last_update_submitted_qc>August 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>common cold</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from waiting rooms of health care providers/clinics between December 2009 and March 2010.</recruitment_details>
      <pre_assignment_details>Participants screened over 2 day period who suffer from an acute respiratory tract infection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mucinex</title>
          <description>2 X 600 MG TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mucinex</title>
          <description>2 X 600 MG TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="378"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="13.91"/>
                    <measurement group_id="B2" value="40.8" spread="15.04"/>
                    <measurement group_id="B3" value="41.0" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator's End of Study Assessment of Treatment</title>
        <description>Yes the investigator would use this treatment for cold symptoms in the future.</description>
        <time_frame>7 days</time_frame>
        <population>MITT defined as all participants receiving at least 1 dose of study medication and had 1 or more efficacy assessment after Baseline. Last observation carried forward method was applied to missing post baseline measurement in the analyses of the MITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex</title>
            <description>Two 600mg tablets taken taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two placebo tablets, identical in appearance to active treatment, taken taken twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's End of Study Assessment of Treatment</title>
          <description>Yes the investigator would use this treatment for cold symptoms in the future.</description>
          <population>MITT defined as all participants receiving at least 1 dose of study medication and had 1 or more efficacy assessment after Baseline. Last observation carried forward method was applied to missing post baseline measurement in the analyses of the MITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Investigator's End-of-Study Assessment NOTE: All assessments of efficacy were considered exploratory and were given equal consideration, and were carried out on both the MITT and PP populations. LOCF method was applied to missing post baseline measurements in analyses of the MITT population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0096</p_value>
            <method>Regression, Logistic</method>
            <method_desc>p-value is from a logistic regression model with terms for treatment group and center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Total number of patients with adverse events that were possibly or probably related.</description>
        <time_frame>7 days</time_frame>
        <population>All participants who received study medication, excluding participants who later returned all the dispensed study medication to the site unused.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex</title>
            <description>2 X 600 MG TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Total number of patients with adverse events that were possibly or probably related.</description>
          <population>All participants who received study medication, excluding participants who later returned all the dispensed study medication to the site unused.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in a 6 Point Severity Scale (0 = None, 1 = Very Mild, 2 = Mild or Slight, 3 = Moderate, 4 = Severe or 5 = As Bad as it Can be) for Cough.</title>
        <description>Mean change from baseline in a 6 point severity scale between treatment groups(0 = None, 1 = Very mild, 2 = Mild or slight, 3 = Moderate, 4 = Severe or 5 = As bad as it can be) for cough.</description>
        <time_frame>Baseline and Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex</title>
            <description>Two 600mg tablets taken taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two placebo tablets, identical in appearance to active treatment, taken taken twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in a 6 Point Severity Scale (0 = None, 1 = Very Mild, 2 = Mild or Slight, 3 = Moderate, 4 = Severe or 5 = As Bad as it Can be) for Cough.</title>
          <description>Mean change from baseline in a 6 point severity scale between treatment groups(0 = None, 1 = Very mild, 2 = Mild or slight, 3 = Moderate, 4 = Severe or 5 = As bad as it can be) for cough.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.14"/>
                    <measurement group_id="O2" value="-0.9" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0293</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>P-value is from a Wilcoxon rank sum test comparing the two treatment groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected through the treatment period. All patients who received at least 1 dose of study medication were included in the safety analysis.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mucinex</title>
          <description>2 X 600 MG TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 TABLETS EVERY 12 HOURS FOR 7 DAYS</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrhythmia supraventricular</sub_title>
                <description>SAE considered not related to study medication. All SAEs in this study were for one patient and related to one event that occurred 17 days prior to treatment start date.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <description>SAE considered not related to study medication. All SAEs in this study were for one patient and related to one event that occurred 17 days prior to treatment start date.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lymphatic duct injury</sub_title>
                <description>SAE considered not related to study medication. All SAEs in this study were for one patient and related to one event that occurred 17 days prior to treatment start date.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>SAE considered not related to study medication. All SAEs in this study were for one patient and related to one event that occurred 17 days prior to treatment start date.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gail Solomon, MS; Director Clinical Development</name_or_title>
      <organization>Reckitt Benckiser Inc.</organization>
      <phone>973-404-2752</phone>
      <email>gail.solomon@reckittbenckiser.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

